The company has conducted the first overnight sleep studies of an OSA patient with and without the StimAire device. Credit: Africa Studio/Shutterstock.com.

Neuromodulation company StimAire has concluded the first-in-human study of an injectable stimulator for obstructive sleep apnea (OSA) in Australia.

The trial evaluated the safety of the injection procedure, the approach feasibility and the operation of the patented device.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

No adverse events were observed during the study and no significant pain or discomfort was noticed from the injection procedures.

The company has also conducted the first overnight sleep studies of an OSA patient with and without the StimAire device modulating the hypoglossal nerve during the night.

StimAire president and CTO Tarek Makansi said: “We are grateful to this team for advancing non-surgical treatments that stimulate peripheral nerves. The ultimate goals are replacement of pacemaker-like devices and universal access to advanced treatments.”

The device has been designed to modulate peripheral nerves, such as the hypoglossal, utilising a tiny, battery-free, injectable receiver/stimulator that is activated by a small wearable.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Readily available components can be used to build StimAire’s system. With the help of a 17-gauge needle, the tiny injectable is placed near the nerve under the guidance of ultrasound.

StimAire chief clinical officer Robert Dean said: “After developing this injection procedure for StimAire at the University of Arizona College of Medicine, I was delighted to see these results.

“This technology has the potential to move treatments like this from the operating room to the doctor’s office, lowering the cost of care and enabling immediate recovery.”

Through the Sponsored Research Program, StimAire collaborated with the University of Arizona College of Medicine – Tucson for its preclinical work with physiology professors Andrew Fuglevand and Fiona Bailey.